Immunomodulation by SanPharma fungal metabolic products

Journal of Alternative and Complementary Medicine

Volumn 12, Issue 4, 2006, Pages 409-416

  Jensen, Gitte S ^a   Hart, Aaron N ^b  

^a Holger NIS Inc   (Canada)

^b NIS Labs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPERGILLUS COMBINATION; CD25 ANTIBODY; CD3 ANTIBODY; CD56 ANTIBODY; CD69 ANTIBODY; CYCLOOXYGENASE 2; DYE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; MUCOR EXTRACT; NATURAL PRODUCT; NOTATUM; PHK 26; PROPIDIUM IODIDE; QUENTANS; ROQUEFORTI; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIVISION; CELL LYSATE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INTERFERON PRODUCTION; LEUKOCYTE; MITOGENESIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOLOGICAL RESPONSE MODIFIERS; CELL EXTRACTS; COMPLEMENTARY THERAPIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FUNGI; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; RECEPTORS, INTERLEUKIN-2;

EID: 33744501507     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2006.12.409     Document Type: Article

References (44)

1. Punj V, Saint-Dic D, Daghfal S, Kanwar JR. Microbial-based therapy of cancer: A new twist to age old practice. Cancer Biol Ther 2004;3:708-714.
2. Samuilov VD. Microbial therapy of cancer: Induction of apoptosis, recombinant vaccines, and inhibition of angiogenesis. Biochemistry 2003;68:958-962.
3. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964-969.
4. Kulcsar G, Nasz I, Tenke P, Csata S. Follow-up of the effect of BCG vaccine treatment in bladder tumour patients. Acta Microbiol Hung 1993;40:151-157.
5. Zlotta AR, Drowart A, Huygen K, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 1997;109:157-165.
6. de Boer EC, De Reijke TM, Vos PC, et al. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell-wall skeletons (Rubratin) and bacillus Calmette-Guerin as therapy for superficial bladder cancer: A comparative study. Clin Infect Dis 2000;(suppl 3):S109-S114.
7. Altundag K, Mohamed AS, Altundag O, et al. SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients. Med Hypoth 2005;64:248-251.
8. Batoni G, Bottai D, Esin S, et al. Purification, biochemical characterization and immunogenicity of SA5K, a secretion antigen of Mycobacterium tuberculosis. Scand J Immunol 2002;56:43-51.
9. Lu SY, Sui YF, Li ZS, et al. Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: An in vitro study. World J Gastroenterol 2004;10:53-57.
10. Pulaski BA, Terman DS, Khan S, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000;60;2710-2715.
11. Rosendahl A, Kristensson K, Carlsson M, et al. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Int J Cancer 1999;81:156-163.
12. Ma W, Yu H, Wang Q, et al. A novel approach for cancer immunotherapy: Tumor cells with anchored superantigen SEA generate effective antitumor immunity. J Clin Immunol 2004;24:294-301.
13. O'Brien ME, Saini A, Smith IE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000;83:853-857.
14. Tarrant JP, Walsh MJ, Blanchard MC, et al. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A. Int J Oncol 2004;25:1693-1699.
15. Enderlein G. Bacteria Cyclogeny: Prolegomena to a Study of the Structure, Sexual and Asexual Reproduction and Development of Bacteria. Original German ed 1916; cited references published 1894-1925; English version: Prescott, AZ: Enderlein Enterprises, Inc., 1999.
16. Onwuamaegbu ME, Belcher RA, Soare C. Cell wall-deficient bacteria as a cause of infections: A review of the clinical significance. J Int Med Res 2005;33:1-20.
17. Greenstein RJ. Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis 2003;3:507-514.
18. Koch AL. Cell wall-deficient (CWD) bacterial pathogens: Could amylotrophic lateral sclerosis (ALS) be due to one? Crit Rev Microbiol 2003;29:215-221.
19. Mattman LH. Cell Wall Deficient Forms: Stealth Pathogens, 3rd ed. Boca Raton, FL: CRC Press, 2001.
20. Macomber PB. Cancer and cell wall deficient bacteria. Med Hypoth 1990;32:1-9.
21. Duncan MJ. Genomics of oral bacteria. Crit Rev Oral Biol Med 2003;14:175-187.
22. Colaizy TT, Kuforiji T, Sklar RS, Pillers de AM. PCR methods in clinical investigations of human ureaplasmas: A minireview. Mol Genet Metab. 2003;80:389-397.
23. Jensen G. Microscopy and the search for the soul. Townsend letter for doctors and patients. 2004;246:110-114.
24. Reddy RV, Sharma RP. Effects of aflatoxin B1 on murine lymphocytic functions. Toxicology 1989;54:31-44.
25. Heiligtag SJ, Bredehorst R, David KA. Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ 2002;9:1017-1025.
26. Green CJ. Immunosuppression with cyclosporin A: A review. Diagn Histopathol 1981;4:157-174.
27. Truffa-Bachi P, Lefkovits I, Frey JR. Proteomic analysis of T cell activation in the presence of cyclosporine A: Immunosuppressor and activator removal induces de novo protein synthesis. Mol Immunol 2000;37:261.
28. Sutton P, Newcombe NR, Waring P, Mullbacher A. In vivo immunosuppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi. Infect Immunol 1994;62:1192-1198.
29. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot 1994;47:208-215.
30. Singh SB, Ondeyka JG, Tsipouras N, et al. Hinnuliquinone, a C2-symmetric dimeric non-peptide fungal metabolite inhibitor of HIV-1 protease. Biochem Biophys Res Commun 2004;324:108-113.
31. Rey-Ladino J, Koochesfahani KM, Zaharik ML, et al. A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct. Infect Immuno 2005;73:1568-1577.
32. Pommepuy I. Terro F, Petit B, et al. Brefeldin A induces apoptosis and cell cycle blockade in glioblastoma cell lines. Oncology 2003;64:459-467.
33. Woehlecke H, Osada H, Herrmann A, Lage H. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int J Cancer 2003;107:721-728.
34. Liang MC, Bardhan S, Li C, et al. Jesterone dimer, a synthetic derivative of the fungal metabolite Jesterone, blocks activation of transcription factor nuclear factor kappaB by inhibiting the inhibitor of kappaB kinase. Mol Pharmacol 2003;64:123-131.
35. Lopez-Franco O, Suzuki Y, Sanjuán G, et al. Nuclear factor kB inhibitors as potential novel anti-inflammatory agents for the treatment of immune glomerulonephritis. Am J Pathol. 2002;161:1497-1505.
36. Woo JH, Park JW, Lee SH, et al. Dykellic acid inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting nuclear factor kappa B transcriptional activity. Cancer Res 2003;63:3430-3434.
37. Reddy MP, Webb EF, Cassait D, et al. Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses. Int J Immunopharmacol 1994;16:795-804.
38. Ruitenberg JJ, Waters CA. A rapid flow cytometric method for the detection of intracellular cyclooxygenases in human whole blood monocytes and a COX-2 inducible human cell line. J Immunol Meth 2003;274(1-2):93-104.
39. Marzio R, Mauel J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol 1999;21:565-582.
40. Testi R, D'Ambrosio D, De Maria R, Santoni A. The CD69 receptor: A multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 1994;15:479-83.
41. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005;26:136-140.
42. Clausen J, Vergeiner B, Enk M, et al. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology 2003;207:85-93.
43. Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9:533-539.
44. Smedsgaard J, Nielsen J. Metabolite profiling of fungi and yeast: From phenotype to metabolome by MS and informatics. J Exp Bot 2005;56:273-286.